๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer

โœ Scribed by Alice De Sanctis; Laurent Taillade; Stephane Vignot; Silvia Novello; Rosa Conforti; Jean Philippe Spano; Giorgio Vittorio Scagliotti; David Khayat

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
172 KB
Volume
117
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Prognostic implications of cell cycle-re
Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer
โœ Sherif Mohamed; Kazuhiro Yasufuku; Kenzo Hiroshima; Takahiro Nakajima; Shigetosh ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 254 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND. Patients who have pathologic N2 (pN2) nonsmall cell lung cancer (pN2 NSCLC) represent a heterogeneous group with regard to prognosis and treatment. Molecular features of NSCLC seem to be of interest. For the current study, to select an appropriate therapeutic strategy fo

Molecular determinants of response to RT
Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer
โœ Niels Reinmuth; Michael Meister; Thomas Muley; Martin Steins; Michael Kreuter; F ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 141 KB

## Abstract Receptor tyrosine kinases (RTKs) are essential components of the cellular signaling apparatus and are often mutated or otherwise deregulated in nonsmall cell lung cancer (NSCLC). These receptors are not solely expressed by cancer cells but also by multiple other cell types, including st

EGFR genetic heterogeneity of nonsmall c
EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance
โœ Shi-Xu Jiang; Kazuya Yamashita; Michiko Yamamoto; Chun-Ji Piao; Atsuko Umezawa; ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 308 KB ๐Ÿ‘ 1 views

## Abstract Gefitinib is dramatically effective for nonsmall cell lung cancers (NSCLCs) with activating mutations of the epidermal growth factor receptor (__EGFR__) gene, but these tumors eventually develop drug resistance, attributable to a secondary T790M mutation or acquired __MET__ amplificatio